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Abstract
Background: Primary aldosteronism (PA) is associated with increased cardiovascular 
morbidity, presumably due to left ventricular (LV) hypertrophy and fibrosis. However, the 
degree of fibrosis has not been extensively studied. Cardiac magnetic resonance imaging 
(CMR) contrast enhancement and novel sensitive T1 mapping to estimate increased 
extracellular volume (ECV) are available to measure the extent of fibrosis.
Objectives: To assess LV mass and fibrosis before and after treatment of PA using CMR 
with contrast enhancement and T1 mapping.
Methods: Fifteen patients with newly diagnosed PA (PA1) and 24 age- and sex-matched 
healthy subjects (HS) were studied by CMR with contrast enhancement. Repeated 
imaging with a new scanner with T1 mapping was performed in 14 of the PA1 and 20 
of the HS median 18 months after specific PA treatment and in additional 16 newly 
diagnosed PA patients (PA2).
Results: PA1 had higher baseline LV mass index than HS (69 (53–91) vs 51 (40–72) g/m2;  
P < 0.001), which decreased significantly after treatment (58 (40–86) g/m2; P < 0.001 
vs baseline), more with adrenalectomy (n = 8; −9 g/m2; P = 0.003) than with medical 
treatment (n = 6; −5 g/m2; P = 0.075). No baseline difference was found in contrast 
enhancement between PA1 and HS. T1 mapping showed no increase in ECV as a 
myocardial fibrosis marker in PA. Moreover, ECV was lower in the untreated PA2 than HS 
10 min post-contrast, and in both PA groups compared with HS 20 min post-contrast.
Conclusion: Specific treatment rapidly reduced LV mass in PA. Increased myocardial 
fibrosis was not found and may not represent a common clinical problem.
Introduction
Primary aldosteronism (PA) has been recognized as the 
most common cause of secondary hypertension (HT), 
with estimated prevalence of 5–12% of all hypertensive 
subjects (1, 2). In patients with refractory HT, PA may be 
present in up to 20% (3). Unilateral aldosterone-producing 
adenoma (APA) and bilateral idiopathic hyperplasia (IHA) 
are the main subtypes; unilateral hyperplasia, inherited 
familial forms of PA and adrenal carcinoma are rare (4). 
Recommended treatment is adrenalectomy in unilateral 
PA and medical treatment with mineralocorticoid receptor 
antagonists in bilateral PA.
Several studies have demonstrated that PA patients 
have increased cardiovascular and renal morbidity 
compared with patients with essential HT (5, 6, 7, 8). 
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Indeed, a recent study also demonstrated increased 
cardiovascular mortality (9). Increased prevalence of 
diabetes mellitus type 2 and the metabolic syndrome 
may also be present (10). Aldosterone, often associated 
with cortisol excess, causes deleterious effects on the 
cardiovascular system and increases metabolic risk, with 
end-organ damage that is at least partly independent 
of aldosterone effect on blood pressure (BP) (11). 
Experimental rat studies first demonstrated that 
chronic aldosterone infusion in the setting of high-salt 
intake induced oxidative stress and caused myocardial 
inflammation, accumulation of fibrillary collagen and 
subsequent interstitial fibrosis independent of the BP 
elevation (12, 13, 14). The cardiac injury was reversed 
either with adrenalectomy or mineralocorticoid receptor 
antagonist treatment (15). Subsequent echocardiographic 
studies have demonstrated increased left ventricular (LV) 
mass in PA compared with essential HT with similar BP (16). 
Echocardiographic videodensitometric and ultrasonic 
backscatter signal analyses have shown alterations in 
myocardial texture in PA, suggestive of increased collagen 
deposition and fibrosis (17, 18, 19). PA patients have more 
cardiac arrhythmias than in essential HT, presumably 
caused by cardiac fibrosis and/or LV hypertrophy (5, 20).
Specific PA treatment decreases LV mass both 
after adrenalectomy and after medical treatment with 
mineralocorticoid receptor antagonists in the long term, 
while echocardiographic studies with shorter follow-up 
time only showed significant reduction in LV mass after 
adrenalectomy (21, 22). In a recent meta-analysis, no 
difference in reduction of LV mass was found between 
adrenalectomy and mineralocorticoid receptor antagonist 
treatment after an average follow-up of four years, despite 
a larger reduction in BP after adrenalectomy (23).
Cardiac magnetic resonance imaging (CMR) 
offers a highly accurate, non-invasive, 3-dimensional 
assessment of cardiac structure, function and tissue 
characteristics. Contrast enhancement techniques 
including late gadolinium enhancement are accurate 
and reproducible in evaluating the presence of 
irreversible focal myocardial fibrosis/scars caused by 
myocardial infarction or hypertrophic cardiomyopathy 
(24, 25). Contrast enhancement is associated with 
adverse outcomes in several cardiac conditions 
(26, 27). However, the most commonly used 
contrast enhancement technique, late gadolinium 
enhancement, requires a comparison between affected 
and unaffected myocardium and may not be sensitive to 
early, potentially reversible diffuse myocardial fibrosis 
affecting the whole myocardium (28).
Recently, T1 mapping techniques assessing T1 
relaxation times have allowed quantitative assessment 
of tissue composition and detection of both focal and 
diffuse interstitial myocardial fibrosis. T1 mapping 
performed before and after administration of 
gadolinium-based contrast media allows quantification 
of the extracellular volume (ECV), a surrogate measure 
for the extracellular space, which is expanded in 
myocardial fibrosis due to interstitial accumulation of 
collagen type I and III (28, 29).
Two CMR studies applying contrast enhancement 
techniques have revealed results consistent with 
increased myocardial fibrosis in PA, but only one 
applied a quantification technique for enhancement 
assessment (30, 31). One CMR study addressed the 
effect of medical mineralocorticoid receptor antagonist 
treatment in PA on cardiac volume overload and 
LV hypertrophy, with mineralocorticoid receptor 
antagonist treatment causing significant decreases in 
both LV mass and cardiac volumes (32). Further, CMR 
with T1 mapping has been used to evaluate the effect 
of HT and subsequent treatment with spironolactone 
on interstitial myocardial fibrosis in mice (33). Thus, 
the extent of fibrosis induced by PA and its reversibility 
is still incompletely known. We therefore aimed to 
assess myocardial mass and fibrosis in PA, using both 
dynamic contrast enhancement and T1 mapping, 
before and after adrenalectomy or medical treatment 
with mineralocorticoid receptor antagonist.
Subjects and methods
Study participants and design
This study was performed between October 2013 and 
March 2016 at Haukeland University Hospital, Bergen. 
Fifteen patients with recently confirmed PA (PA1) and 
24 age- and sex-matched normotensive healthy subjects 
(HS) were included for baseline CMR with dynamic 
contrast enhancement (CMR1-CE) between October 
2013 and June 2014 (Fig.  1). After completion of this 
substudy, they were invited to a follow-up CMR with 
T1 mapping (CMR2-T1, June 2015–March 2016), 
performed at least one year after the start of specific PA 
treatment. One patient was excluded from follow-up 
due to deterioration of renal function and four HS 
declined follow-up. An additional 17 newly diagnosed 
patients (PA2) were recruited of whom 16 completed the 
protocol.
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Diagnosis and clinical assessment
All PA patients had their diagnosis confirmed by saline 
infusion testing (SIT), and adrenal vein sampling (AVS) 
for subtype differentiation planned or performed at the 
time of study inclusion, according to current guidelines 
(4). Positive SIT was defined as a post-infusion plasma 
aldosterone level >140 pmol/L (34, 35). BP was measured 
in a standardized manner in all study groups, with three 
repetitive measurements in a seated position, after at least 
five minutes rest. Height and weight were recorded for all.
CMR performed with dynamic contrast 
enhancement (CMR1-CE)
PA1 and HS were examined with a 3T GE Signa Excite 
Scanner (Milwaukee, WI, USA). A phased-array cardiac 
coil with eight elements was used. All images were 
obtained during breath-hold with electrocardiography 
(ECG) triggering. For evaluation of LV mass and LV 
volumes, short-axis CINE views were obtained, using a 
Fiesta sequence. A pre-contrast mid-ventricular short-
axis view and a 4-chamber view were then performed 
before a gadolinium-based contrast agent (Gadovist 
1 mmol/mL, Bayer Pharma AG) 0.2 mL/kg body weight 
was administered as an intravenous bolus injection. An 
inversion recovery gradient echo sequence was applied. 
Contrast images in the same views as pre-contrast were 
then acquired at seven consecutive time points (2, 4, 6, 8, 
10, 12 and 14 min) post-contrast.
CMR performed with T1 mapping (CMR2-T1)
The scanner used for the CMR1-CE was replaced in June 
2014. The CMR2-T1 substudy was therefore performed 
with a 3T Siemens Magnetom Skyra (Erlangen, Germany). 
All images were obtained during breath-hold with ECG 
triggering. CINE views were performed using the same slice 
parameters as for the baseline CMR1-CE. The inversion 
recovery-based MOLLI sequence was used for T1 mapping 
(MyoMaps; Siemens, Erlangen) in accordance with the 
recommendations of the Society for Cardiovascular 
Magnetic Resonance (SMR) (36, 37). A native pre-contrast 
T1 mapping mid-ventricular short-axis view was then 
performed before the gadolinium-based contrast agent 
(Gadovist 1 mmol/mL, Bayer Pharma AG) 0.15 mL/kg body 
weight was administered as an intravenous bolus injection. 
Further T1 mapping mid-ventricular short-axis views were 
then performed 10, 15 and 20 min post-contrast.
Figure 1
Study flow chart for the three study groups; PA1, HS and PA2. CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; HS, healthy subjects; PA1, primary aldosteronism group 1; PA2, primary aldosteronism 
group 2.
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ECG, oxygen saturation and pulse were monitored 
continuously during all CMR procedures. BP was measured 
regularly during all image sequences.
Estimation of LV mass, volumes and function
For estimation of LV mass, LV volumes and function, 
the CMR images were analysed by using the software 
Segment, version 1.9 R3697 (http://segment.heiberg.se) 
(38). End-diastole and end-systole were defined and LV 
endo- and epicardial borders were manually delineated 
in all slices in end-diastole and end-systole (excluding 
papillary muscles). Values for LV mass, LV end-diastolic 
volume (LV-EDV), end-systolic volume (LV-ESV), stroke 
volume (LV-SV), cardiac output (CO) and ejection fraction 
(EF) were then calculated, and mass and volumes were 
indexed to body surface area.
Estimation of myocardial fibrosis from contrast 
enhancement images
For the contrast enhancement image acquisition, a 
protocol earlier published by Su and coworkers was 
adopted and slightly modified (31). From mid-ventricular 
short-axis views performed pre- and at the different time 
points post-contrast, three non-overlapping regions of 
interest (ROI) were placed both in the interventricular 
septum and within the LV lumen (Fig. 2A). The average 
signal intensities (SI) both from the interventricular 
septum and the lumen were calculated. The contrast 




SI post-contrast myo SI native − myo
SI post-contrast blood SI native blood−
SI post-contrast myo is the SI of myocardium after 
contrast, SI native myo is the SI of myocardium before 
contrast, SI post-contrast blood is the SI within the LV 
lumen after contrast and SI native blood is the SI within 
the lumen before contrast.
Estimation of myocardial fibrosis  
from T1 mapping
T1 mapping measurements were performed using syngo.
via software (Siemens, Erlangen). One ROI covering 
most of the interventricular septum and one ROI within 
the LV lumen were drawn both from the native pre-
contrast T1 mapping and the post-contrast T1 mapping 
short-axis views (Fig. 2B). The ECV was then calculated as 


















CMR imaging of the heart. (A) Post-contrast short-axis view of the heart 
with three ROIs drawn in the interventricular septum and lumen for 
calculation of contrast enhancement values (substudy CMR1-CE). (B) 
Post-contrast T1 mapping short-axis view of the heart with a ROI drawn 
in the interventricular septum and lumen for calculation of ECV 
(substudy CMR2-T1). CMR1-CE, cardiac magnetic resonance imaging with 
dynamic contrast enhancement; CMR2-T1, cardiac magnetic resonance 
imaging with T1 mapping; ECV, extracellular volume; ROI, region of 
interest.
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 T1 post-contrast myo is the SI of myocardium after 
contrast, T1 native myo is the SI of myocardium before 
contrast, T1 post-contrast blood is the SI within the LV 
lumen after contrast and T1 native blood is the SI within 
the lumen before contrast.
All post-processing measurements for both CMR1-CE 
and CMR2-T1 were performed by two investigators (MG/KS 
or MG/TL), and the mean values of the measurements from 
the two investigators were used for statistical analyses.
Statistical analysis
All parameters are expressed as median and ranges. Student’s 
t-test and Mann–Whitney U test were used to compare 
normally and not normally distributed continuous data 
between two groups, and Wilcoxon signed-rank test for 
within-patient not normally distributed data. One-way 
ANOVA was used to compare continuous data between 
more than two groups. For comparison of categorical 
variables, the chi-square test or Fisher’s exact probability 
test was used. Bland–Altman plots were used for analysing 
the agreement between the measurements performed 
by the two investigators. A deviation of less than 10% 
between the values obtained by the two investigators 
was considered acceptable. P values less than 0.05 were 
considered statistically significant.
Written informed consent was obtained from all 
participants. The study was approved by the Regional 
Committee for Medical and Health Research Ethics 
(REC West/University of Bergen).
Results
Clinical characteristics: CMR with dynamic 
contrast enhancement (CMR1-CE)
The clinical characteristics of PA1 and HS at the time of 
the baseline CMR1-CE are shown in Table 1. PA1 and HS 
did not differ in terms of age or sex, but the PA1 patients 
had higher body mass index (BMI) and higher BP than 
the HS (median BMI 26 (range 22–34) vs 23 (18–27) kg/m2; 
P < 0.001 and BP 138/90 vs 118/75 mmHg; P < 0.001 for 
both systolic and diastolic BP).
In PA1, AVS performed for subtype differentiation 
showed unilateral PA in 9/15 patients, the remaining had 
bilateral (5/15) or not representative (1/15) AVS. Three PA1 
patients had been adrenalectomized within the past three 
months prior to inclusion for CMR1-CE. Five had started 
medical mineralocorticoid receptor antagonist treatment 
within the past 4–7 months, while the remaining had not 
yet started specific PA treatment.
One patient in PA1 had established coronary disease 
at baseline (paroxysmal atrial fibrillation). One had 
experienced several cerebral infarctions before the age 
of 50 years. Two had diabetes mellitus type 2, and two 
had chronic kidney disease, with estimated glomerular 
filtration rates of 47 and 54 (mL/min/1.73 m2) at baseline, 
respectively. One PA patient without a history of coronary 
disease had sequelae from a small cardiac infarction found 
on his CMR. He was referred for cardiac evaluation.
Clinical characteristics: CMR with 
T1 mapping (CMR2-T1)
For PA1, the CMR2-T1 was performed at least one 
year after the start of specific treatment either with 
unilateral adrenalectomy or medical treatment with 
mineralocorticoid receptor antagonists (Table  1). Eight 
of 14 PA1 patients had been adrenalectomized, with 
median 18 (range 12–21) months since adrenalectomy. 
The remaining 6/14 were on medical mineralocorticoid 
receptor antagonist treatment, with median 21 (12–27) 
months since start of this medication. BP at follow-up 
was still significantly higher in the PA1 than in the HS 
group (median BP 134/81 vs 124/73 mmHg; systolic 
BP P = 0.02/diastolic BP P = 0.012), despite a median 
two antihypertensive drugs in the PA1 group. In PA1, 
only small non-significant BP changes appeared after 
treatment, with median systolic BP reduction 7 mmHg; 
P = 0.064 and median diastolic BP reduction 5 mmHg; 
P = 0.148 (not shown).
Among the 16 newly diagnosed patients in PA2 
performing CMR2-T1, AVS showed unilateral disease in 
six patients and bilateral in 10 (Table 1). Only one of the 
newly diagnosed PA patients in PA2 had started specific 
PA treatment with spironolactone two months before the 
CMR2-T1; none in PA2 had yet been adrenalectomized. 
One of the PA2 patients had ischaemic coronary disease 
treated with percutaneous coronary intervention as 
comorbidity, two had atrial fibrillation (one paroxysmal 
and one radiofrequency ablated), and one had diabetes 
mellitus type 1. Median BP was 145/91 mmHg in PA2, 
with median three (0–6) antihypertensive drugs.
LV function and LV mass: CMR with dynamic 
contrast enhancement (CMR1-CE)
The results from LV function and LV mass measured 
with CMR1-CE are listed in Table  2. Baseline LV mass 
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indexed to body surface area differed significantly 
between the PA1 and HS group (LV mass index 69 (53–91) 
vs 51 (40–72) g/m2; P < 0.001). No differences between 
the two groups were found in cardiac function measured 
as LV-EDV index, LV-ESV index, LV-SV index, LV-EF, HR 
or CO index.
Dynamic contrast enhancement  
results (CMR1-CE)
Figure  3 illustrates the contrast enhancement values in 
PA1 and HS measured from 2 to 14 min post-contrast. 
No difference was found in contrast enhancement value 
between PA1 and HS at any time point. For both PA1 and 
HS, the contrast enhancement showed a trend towards 
reduced values from 2 to 14 min post-contrast.
LV function and LV mass-CMR with T1 
mapping (CMR2-T1)
LV function and LV mass indexes for PA1, HS and PA2 
measured with CMR2-T1 are shown in Table  2. At 
follow-up CMR2-T1, PA1 had a significantly reduced LV 
mass index (LV mass index 58 (40–86) g/m2; P < 0.001 vs 
baseline values). LV mass index in PA1 was still higher, 
but no longer significantly different to LV mass index 
in HS (LV mass index 58 (40–86) vs 57 (45–75) g/m2; 
P = ns). When analysing the adrenalectomized (n = 8) 
Table 1 Clinical and biochemical characteristics of PA1, HS and PA2 at substudy CMR1-CE and substudy CMR2-T1.*
 CMR1-CE CMR2-T1
PA1 HS PA1 post-treatment HS PA2
Participants in study group, n 15 24 14 20 16
Characteristics
 Males:females 12:3 17:7 11:3 13:7 12:4
 Age (years) 58 (34–72) 53 (34–70) 59 (36–68) 53 (35–71) 57 (29–72)
 Body mass index (kg/m2) 26 (22–34) 23 (18–27) 26 (23–35) 22 (19–29) 29 (19–36)
 Duration of hypertension (years) 15 (2–25) 0 10 (0–25)
 Systolic blood pressure (mmHg) 138 (123–178) 118 (100–136) 134 (105–180) 125 (105–136) 145 (123–182)
 Diastolic blood pressure (mmHg) 90 (60–108) 75 (61–88) 81 (69–105) 75 (60–94) 91 (75–115)
 Number of antihypertensive drugs (n) 3 (0–5) 0 2 (0–6) 0 3 (0–6)
Biochemistry
 Hypokalaemia (n)** 14 7
 Lowest s-potassium measured (mmol/L) 3.0 (2.3–3.7) 3.6 (2.5–4.0)
 S-potassium (mmol/L) 3.3 (2.8–4.4) 4.3 (3.8–5.3) 3.7 (3.3–4.7)
 P-aldosterone (pmol/L) 680 (384–2252) *** 412 (57–3420) 293 (116–855) 490 (277–2110)
 P-renin activity (µg/L/h) 0.1 (0.1–3.0) *** 0.8 (0.2–26.7) 1.7 (0.3–4.0) 0.4 (0.1–0.8)
 ARR (pmol/µg/h)**** 6065 (168–22,520) 288 (21–2650) 224 (53–662) 1580 (610–3700)
 Direct renin concentration (mIE/L)**** 2.2 (2.0–8.2)
 ARR (pmol/mIE)**** 126 (46–1055)
 Post-SIT aldosterone at diagnosis (pmol/L) 348 (169–1144) 297 (167–1460)
AVS results PA patients
 AVS lateralization (n) 9 8 6
 AVS non-lateralized (n) 5 5 10
 AVS not representative (n) 1 1 0
Treatment status PA patients
 Adrenalectomized (n) 3 8 0
 Months since adrenalectomy 2.5 (0.5–3.0) 18 (12–21)
 MR antagonist treatment (n) 5 6 1
 Spironolactone (daily dose in mg) 50 (25–100) 50 (25–75) 25
 Eplerenone (daily dose in mg) 100 (n = 1)
 Months since start MR antagonist treatment 6 (4–7) 21 (12–27) 2
 Not started specific treatment (n) 7 0 15
*Data shown as median (range) or as number; **hypokalaemia was defined as s-potassium <3.5 mmol/L at least once; ***p-aldosterone and p-renin 
activity in the healthy subjects (HS) were measured at the time of the CMR2-T1; ****ARR calculated with plasma renin activity: normal range <750 pmol/
µg/h. The renin assay was in February 2016 changed from plasma renin activity (Gammacoat, Diasorin) to direct renin concentration (LIAISON Direct 
Renin, DiaSorin). 7/16 of the patients in the PA2 group therefore had their renin measured as direct renin concentration. ARR calculated with direct 
renin concentration: normal range <50 pmol/mIE with aldosterone <300 pmol/L, normal range <35 pmol/mIE with aldosterone >300 pmol/L.
ARR, aldosterone–renin ratio; AVS, adrenal vein sampling; CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; HS, healthy subjects; MR antagonist, mineralocorticoid receptor antagonist; PA1, 
primary aldosteronism group 1; PA2, primary aldosteronism group 2; SIT, saline infusion test.
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and the medically treated (n = 6) PA1 patients separately, 
the adrenalectomized patients had a larger and highly 
significant reduction of LV mass index, compared with the 
medically treated patients who showed a trend towards, 
but had no significant reduction in LV mass index 
(adrenalectomized PA1 median reduction of LV mass 
index −9 g/m2; P = 0.003 vs mineralocorticoid receptor 
antagonist treated PA1 reduction of LV mass index −5 g/m2; 
P = 0.075, not shown).
The newly diagnosed PA2 group had significantly 
higher LV mass index at CMR2-T1 than both the treated 
PA1 and HS (PA2 median LV mass index 70 (50–92); 
P = 0.019 vs treated PA1; PA2 vs HS P < 0.001).
For PA1, LV-EDV index showed a non-significant 
trend of reduction from baseline CMR1-CE to follow-up 
CMR2-T1 (P = 0.076). In the HS group, LV-EDV 
remained unchanged (Table  2). When comparing the 
adrenalectomized vs medically mineralocorticoid receptor 
antagonist-treated PA patients, only the PA1 patients 
treated with mineralocorticoid receptor antagonists had a 
significant reduction in LV-EDV index (medically treated 
PA1 median change in LV-EDV index −14 mL/m2; P = 0.03, 
vs adrenalectomized PA1 −7 mL/m2; P = 0.54 (not shown)).
T1 mapping results (CMR2-T1)
The results from the T1 mapping performed with CMR2-T1 
for both treated PA1, newly diagnosed PA2 and HS are 
shown in Fig. 4. No increase in ECV as a CMR marker of 
interstitial fibrosis was found in either PA1 or PA2 compared 
with HS. On the contrary, ECV was significantly lower in 
the untreated PA2 than in the HS 10 min post-contrast, 
and in both PA groups compared with the HS group 20 min 
post-contrast. No significant difference in ECV was found 
between PA1 and PA2 at any time-point post-contrast.
Discussion
In this study, we applied CMR to explore the effects of PA, 
before and after treatment, on myocardial morphology 











P value PA1 
vs HS 
(CMR1-CE)**
P value PA1 
post-treatment 





PA1 (n = 15)
 
 






HS (n = 20)
 
 
PA2 (n = 16)
LV-EDV index (mL/m2) 85 (72–109) 91 (62–120) 79 (61–104) 91 (76–121) 97 (69–116) ns ns
LV-ESV index (mL/m2) 33 (20–52) 37 (24–51) 31 (20–47) 37 (23–54) 38 (19–51) ns ns
LV-SV index (mL/m2) 53 (33–68) 53 (38–73) 48 (33–66) 53 (36–72) 57 (49–86) ns ns
LV-EF (%) 62 (45–74) 62 (52–67) 60 (48–73) 60 (42–71) 62 (51–74) ns ns
HR (beats/min) 64 (39–87) 66 (50–84) 63 (44–80) 53 (38–66) 54 (42–68) ns ns
CO index (L/min/m2) 3.5 (2.2–4.4) 3.5 (2.3–5.0) 2.6 (2.0–4.5) 3.0 (1.9–4.0) 3.1 (2.0–4.8) ns ns
LV mass index (g/m2) 69 (53–91) 51 (40–72) 58 (40–86) 57 (45–75) 70 (50–92) <0.001 <0.001
*Data shown as median (range); **Student’s t-test used.
CO, cardiac output; CMR, cardiac magnetic resonance imaging; CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; HS, healthy 
subjects; LV, left ventricular; PA1, primary aldosteronism group 1; PA2, primary aldosteronism group 2; SV, stroke volume.
Figure 3
Box plots of dynamic contrast enhancement distribution at 2–14 min 
post-contrast for PA1 and HS (substudy CMR1-CE). The horizontal line 
indicates the median, the box represents the 25th–75th percentiles, and 
the whiskers represent the minimum and maximum value. Circles and 
asterisk indicate outliers. CMR1-CE, cardiac magnetic resonance imaging 
with dynamic contrast enhancement; HS, healthy subjects; PA1, primary 
aldosteronism group 1.
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and function. The myocardial hypertrophy observed 
at diagnosis rapidly normalized with treatment, most 
pronounced after adrenalectomy. However, surprisingly 
neither dynamic contrast enhancement nor T1 mapping 
revealed myocardial fibrosis in newly diagnosed PA 
compared with HS.
The finding of lack of increased myocardial fibrosis 
in PA contrasts both earlier experimental studies 
and human ultrasonographic backscatter signal and 
videodensitometric studies (12, 13, 17, 18, 19). However, 
CMR is the recommended imaging modality for 
myocardial tissue characterization, and our findings also 
contrast two former 1.5 Tesla CMR studies using contrast 
enhancement techniques, which both showed higher 
contrast enhancement in PA than in essential hypertensive 
patients and healthy controls (30, 31). However, in one of 
these studies (30), contrast enhancement was measured 
as the presence of a non-infarct diffuse pattern of LGE, 
which is a less objective method to evaluate diffuse 
myocardial fibrosis (28). The other study used the same 
formula for dynamic contrast enhancement as we (31). 
However, there is still no universally accepted optimal 
dynamic contrast enhancement quantification technique, 
which may be reflected in the discrepancy of our results 
despite applying the same technique (28, 39). The PA 
patients in the two former studies were slightly younger 
than both our PA groups, but had a similar duration of 
HT. Possible differences in PA subtypes, severity of PA 
phenotype, gender distribution or severity of HT might 
also have influenced our discrepant results.
The recent developments of T1 mapping techniques 
enable quantitative assessments of changes in myocardial 
tissue composition and the presence of diffuse myocardial 
fibrosis, with estimation of the ECV percentage. T1 
mapping thus facilitates a non-invasive alternative 
to myocardial biopsies and histochemical analyses 
(40). If myocardial fibrosis is present, expansion of the 
extracellular interstitial space should yield higher ECV. 
ECV has been shown to correlate well with histological 
fibrosis in several cardiac diseases (28), and this is the 
first time this technique is used to study PA. Similar to 
dynamic contrast enhancement, T1 mapping showed no 
evidence of increased myocardial fibrosis. In contrast, 
we found that both the newly diagnosed and treated PA 
group in our study had, at 20 min post-contrast, lower 
ECV than the healthy subjects. Thus, the left ventricular 
intracellular fraction is increased, which indicates 
more pronounced cardiomyocyte hypertrophy than 
ECV increase in both PA groups. Our findings clearly 
challenge the widely held conception that substantial 
myocardial fibrosis is typical in PA. Myocardial interstitial 
fibrosis caused by aldosterone and salt loading has been 
histologically proven in experimental animal studies (12, 
41, 42). Human myocardial fibroblasts may differ from 
rodents when exposed to excess amounts of aldosterone, 
and the experimental levels of aldosterone and sodium in 
rodents may not reflect the exposure in humans with PA. 
To our knowledge, only one small human post-mortem 
study of five patients of high age with adrenal adenomas 
with suspected PA due to concomitant HT and low or low-
normal s-potassium levels has been performed. That study 
showed histological fibrosis both in the myocardium as 
well as in the pancreas and lungs (43). However, ageing is 
associated with progressive fibrosis (44), and in the former 
study, the patients were approximately ten years older than 
in our study. Moreover, significant fibrosis may well be an 
end stage of long-standing and untreated PA. Furthermore, 
the fact that risks of cardiovascular complications in 
untreated PA are reduced to the same level as in essential 
HT after specific PA treatment, supports that irreversible 
fibrosis is not present (20). Essentially, this is the first study 
Figure 4
Box plots of the ECV distribution from T1 mapping at 10, 15 and 20 min 
post-contrast for PA1 (post-treatment), PA2 (newly diagnosed) and HS 
(substudy CMR2-T1). The horizontal line indicates the median, the box 
represents the 25th–75th percentiles, and the whiskers represent the 
minimum and maximum value. *P < 0.05 vs HS. CMR2-T1, cardiac magnetic 
resonance imaging with T1 mapping; ECV, extracellular volume; HS, 
healthy subjects; PA1, primary aldosteronism group 1; PA2, primary 
aldosteronism group 2.
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to apply CMR T1 mapping with quantitative assessment of 
ECV, which is the recommended gold standard parametric 
mapping technique for evaluation of diffuse myocardial 
fibrosis in a newly published consensus statement (37).
We also measured the effect of PA treatment on LV mass 
index and found a significant reduction after treatment. 
Regression of LV hypertrophy is associated with improved 
cardiovascular outcome in essential HT (45). When 
analysing the adrenalectomized and medically treated 
PA patients separately, reduction of LV mass index was 
highly significant only for the adrenalectomized group. 
Although not significant, we observed a strong trend 
towards reduction of LV mass index also in the medically 
treated group, with a median follow-up time of less than 
two years. These findings are in accordance with another 
CMR study, which showed significant regression of LV 
mass index in patients with suspected PA both after 3- 
and 6-month treatment with mineralocorticoid receptor 
antagonists (32). One echocardiographic study showed 
no significant change of LV mass index one year after 
start of mineralocorticoid receptor antagonist treatment, 
whereas another large study showed borderline significant 
reduction in LV mass index in medically treated PA after 
a median follow-up of 36 months (21, 22). The regression 
in LV mass after specific PA treatment occurred despite no 
significant reduction in BP. In the Framingham Offspring 
study, the aldosterone-to-renin ratio was identified as a 
key correlate of LV hypertrophy (46). Studies conducted 
in patients with essential HT have similarly shown a direct 
relationship between aldosterone levels and changes in 
LV geometry (47, 48). Thus, the reduction of LV mass after 
PA treatment is probably due to both reduced aldosterone 
levels and improved BP.
In the PA patients, we found a significant reduction 
in LV-EDV index only in the medically treated subgroup, 
in accordance with a former study (32). PA is associated 
with increased plasma brain natriuretic peptide and 
intracardiac volume overload, which is reversed by 
mineralocorticoid receptor antagonists or adrenalectomy. 
In the former study, the intracardiac volume overload was 
refractory to thiazides, while low doses of spironolactone 
showed a prominent diuretic effect. Small numbers may 
explain why no difference was found in LV-EDV index in 
the adrenalectomized patients in the current study.
A limitation of our study is that not all PA1 patients were 
completely treatment naïve at the time of the CMR1-CE; 
some had already undergone adrenalectomy and some had 
commenced treatment with mineralocorticoid receptor 
antagonists shortly before. Among the newly diagnosed 
PA2 patients participating in the CMR2-T1, only one 
patient had started specific PA treatment shortly before 
his CMR. PA patients with unilateral disease often have a 
more florid phenotype, and the relatively large proportion 
of patients with bilateral disease in PA2 may represent a 
less severe form of PA, which may have influenced the T1 
mapping results.
The lack of an additional hypertensive control 
group is a limitation. If evidence of increased myocardial 
fibrosis in PA compared with in healthy subjects had 
been found, such a control group would have been 
necessary to determine whether these changes were 
caused by aldosterone excess or haemodynamic effects 
of hypertension itself. Furthermore, it could have shown 
whether the lower ECV in both treated and untreated 
PA post-contrast would be caused by aldosterone or 
haemodynamic effects of hypertension per se.
The replacement of the CMR scanner used at baseline 
with a new scanner for the follow-up CMR2-T1, may 
pose a further limitation. On the other hand, the use 
of two different techniques to study myocardial fibrosis 
with overlapping results certainly strengthens the study. 
A further asset is that all post-image analyses were 
performed by two different investigators. A limitation is 
that the dynamic contrast enhancement technique and 
T1 mapping were applied at different time points of the 
study, and we were therefore unable to examine the study 
participants with these two methods simultaneously, 
which would have given direct comparisons of the two 
methods. The PA1 patients had all received specific 
PA treatment for at least a year when examined with 
T1 mapping but were relatively treatment naïve when 
examined with dynamic contrast enhancement, which 
precludes direct comparisons of contrast enhancement 
and T1 mapping results in this group. In order to examine 
treatment-naïve PA patients with T1mapping, we 
therefore included also the newly diagnosed PA2 group 
for the CMR2-T1.
Habitual dietary sodium intake of the study 
participants was not recorded, and it is unknown whether 
the PA patients had been given specific dietary counselling 
to reduce their salt intake prior to or during the study 
period. In experimental animal studies, high levels of 
aldosterone infusion did not cause cardiovascular damage 
when sodium intake was very low (12). Similarly, in 
humans, extraordinarily high aldosterone concentrations 
in populations with chronic sodium deficiency was not 
associated with cardiovascular damage (49). A recent 
study demonstrated that dietary salt intake influenced 
the reduction of LV mass after PA treatment (50). Thus, 
dietary sodium intake may have influenced our results.
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In conclusion, specific PA treatment rapidly reduced 
LV mass. Both dynamic contrast enhancement and, 
notably, the recommended T1 mapping, showed no 
evidence of increased myocardial fibrosis in PA patients 
compared with healthy individuals. Thus, myocardial 
fibrosis does not seem to be a significant clinical problem 
in PA if diagnosed and treated within time frames 
commonly used in clinical practice.
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